DrugPatentWatch Database Preview

Details for Patent: 7,612,176

Which drugs does patent 7,612,176 protect, and when does it expire?

Patent 7,612,176 protects BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in two NDAs.

This patent has twenty-three patent family members in thirteen countries.

Summary for Patent: 7,612,176

Title:	Polymer-based sustained release device
Abstract:	This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Inventor(s):	Wright; Steven G. (Madeira, OH), Christensen; Troy (Mason, OH), Yeoh; Thean (Foxboro, MA), Rickey; Michael E. (Loveland, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Costantino; Henry R. (Woodinville, WA)
Assignee:	Alkermes, Inc. (Cambridge, MA)
Application Number:	11/826,535
Patent Claim Types: see list of patent claims	Composition; Use;

Drugs Protected by US Patent 7,612,176

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE	➤ Sign Up
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE	➤ Sign Up
Astrazeneca Ab	BYDUREON BCISE	exenatide	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,612,176

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,431,685	Polymer-based sustained release device	➤ Sign Up
7,456,254	Polymer-based sustained release device	➤ Sign Up
8,461,105	Polymer-based sustained release device	➤ Sign Up
8,293,871	Poly(lactide-co-glycolide) based sustained release microcapsules comprising a polypeptide and a sugar	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 7,612,176

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005235100	➤ Sign Up
Brazil	PI0509946	➤ Sign Up
Canada	2560874	➤ Sign Up
Canada	2798552	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,612,176

For more information try a trial or see the plans and pricing